Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation

Clinical Chemistry

Volumn 53, Issue 5, 2007, Pages 823-828

  Lee, Hong Kee ^a   Lewis, Lionel D ^a   Tsongalis, Gregory J ^a   Schur, Bernard C ^b   Jannetto, Paul J ^b   Wong, Steven H ^b   Yeo, Kiang Teck J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ARTICLE; DNA DETERMINATION; DNA SEQUENCE; GENE DELETION; GENE DUPLICATION; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NANOTECHNOLOGY; POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DUPLICATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NANOTECHNOLOGY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SEQUENCE DELETION;

EID: 34248383914     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.081539     Document Type: Article

References (25)

1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
2. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
3. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP 2D6 Allele Nomenclature, 2001. http://www.cypalleles. ki.se/cyp2d6.htm (accessed July 3, 2006).
4. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005;78: 559-81.
5. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
6. van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 36:722-9, 1999.
7. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
8. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003;19:660-6.
9. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31.
10. Frueh FW, Huang SM, Lesko U. Regulatory acceptance of toxicogenomics data. Environ Health Perspect 2004;112:A663-4.
11. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 2004;3:763-9.
12. Ruano G. Quo vadis personalized medicine? Personalized Med 2004;1:1-7.
13. Ferrari M, Cremonesi L, Bonini P, Foglieni B, Stenirri S. Single-nucleotide polymorphism and mutation identification by the Nanogen microelectronic chip technology. Methods Mol Med 2005; 114:93-106.
14. Erali M, Schmidt B, Lyon E, Wittwer C. Evaluation of electronic microarrays for genotyping factor V, factor II, and MTHFR. Clin Chem 2003;49:732-9.
15. Huang Y, Shirajian J, Schroder A, Yao Z, Summers T, Hodko D, et al. Multiple sample amplification and genotyping integrated on a single electronic microarray. Electrophoresis 2004;25:3106-16.
16. Schrijver I, Lay MJ, Zehnder JL. Diagnostic single nucleotide polymorphism analysis of factor V Leiden and prothrombin 20210G > A. A comparison of the Nanogen Electronic Microarray with restriction enzyme digestion and the Roche LightCycler. Am J Clin Pathol 2003;119:490-6.
17. Jain KK. Applications of AmpliChip CYP450. Mol Diagn 2005;9: 119-27.
18. Soderback E, Zackrisson AL, Lindblom B, Alderborn A. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem 2005;51:522-31.
19. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002;1:49-59.
20. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996;6:319-28.
21. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
22. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4.
23. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005;207:52-6.
24. Linder MW, Valdes R, Jr. Pharmacogenetics in the practice of laboratory medicine. Mol Diagn 1999;4:365-79.
25. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-50.